百濟神州(06160.HK)第四季度全球總收入增長78% 實現全年非GAAP經營利潤為正
格隆匯2月27日丨百濟神州(06160.HK)公吿，2024年第四季度，公司全球總收入達11億美元，同比增長78%，全年全球總收入達38億美元，同比增長55%；GAAP經營虧損持續收窄，實現全年非GAAP經營利潤為正。
百悦澤第四季度全球銷售額達8.28億美元，同比增長100%，全年全球銷售額達26億美元，同比增長105%；BCL2抑制劑sonrotoclax和BTK CDACBGB-16673已推進至關鍵性項目階段。
經調整後（即不包括加速折舊），2024年第四季度和全年的產品銷售毛利率分別增至87.4%和85.5%，而上年同期分別為83.7%和83.2%。
2024年第四季度和全年，與在研項目授權引進資產相關的預付款和里程碑付款分別為6,300萬美元和1.14億美元，上年同期分別為3,180萬美元和4,680萬美元。
第四季度推動6款新分子實體(NME)進入臨牀開發階段，全年共有13款；預計2025年上半年將有多個創新性實體瘤項目進行數據讀出。
公司2025年全年收入指引為49億至53億美元，同時重申預計GAAP經營利潤為正且經營活動產生現金流為正。
“公司第四季度和全年業績取得強勁增長，充分彰顯了我們作為全球腫瘤治療領導者的實力。百悦澤的持續成功，以及我們開發的業內最豐富的實體瘤管線之一，進一步鞏固了這一領先地位。多項數據預計將在今年讀出”。百濟神州聯合創始人、董事長兼首席執行官歐雷強先生表示，“目前，百悦澤在美國慢性淋巴細胞白血病(CLL)新患者治療領域中處於絕對領先地位，在所有BTK抑制劑中擁有最廣泛的適應症。作為公司血液學領域的基石藥物，百悦澤與後期管線BCL2抑制劑sonrotoclax和潛在同類首創BTK CDAC還展示出巨大的聯合治療潛力。與此同時，我們充分利用多特異性抗體、蛋白降解劑和抗體偶聯藥物等在內的研發平台，加速推進未來在乳腺癌、肺癌和胃腸道癌等治療領域的佈局。2025年對於公司而言是一個關鍵的轉捩點，我們預計今年在美國公認會計原則(GAAP)下實現經營利潤和經營性現金流為正，同時我們計劃啟用公司新英文名稱BeOne，並已在納斯達克啟用新股票代碼ONC”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
